Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
9031 | BAZ1B | Dong_P1 | Human | Prostate | Tumor | 4.05e-12 | 4.14e-02 | 0.035 |
9031 | BAZ1B | Dong_P3 | Human | Prostate | Tumor | 7.95e-04 | 6.70e-02 | 0.0278 |
9031 | BAZ1B | Dong_P5 | Human | Prostate | Tumor | 1.38e-27 | 1.76e-01 | 0.053 |
9031 | BAZ1B | GSM5353216_PA_PB1A_Pool_1_3_S50_L002 | Human | Prostate | Tumor | 4.70e-02 | 6.46e-01 | 0.159 |
9031 | BAZ1B | GSM5353221_PA_PB2A_Pool_1_3_S25_L001 | Human | Prostate | Tumor | 1.16e-09 | 6.89e-01 | 0.1633 |
9031 | BAZ1B | GSM5353222_PA_PB2B_Pool_1_3_S52_L002 | Human | Prostate | Tumor | 3.22e-09 | 6.37e-01 | 0.1608 |
9031 | BAZ1B | GSM5353223_PA_PB2B_Pool_2_S26_L001 | Human | Prostate | Tumor | 8.82e-07 | 6.64e-01 | 0.1604 |
9031 | BAZ1B | GSM5353224_PA_PR5186_Pool_1_2_3_S27_L001 | Human | Prostate | Tumor | 1.34e-04 | 5.69e-01 | 0.1621 |
9031 | BAZ1B | GSM5353225_PA_PR5196-1_Pool_1_2_3_S53_L002 | Human | Prostate | Tumor | 9.13e-03 | 5.64e-01 | 0.1619 |
9031 | BAZ1B | GSM5353227_PA_PR5199-193K_Pool_1_2_3_S55_L002 | Human | Prostate | Tumor | 7.11e-12 | 7.38e-01 | 0.1602 |
9031 | BAZ1B | GSM5353232_PA_PR5249_T1_S3_L001 | Human | Prostate | Tumor | 1.27e-03 | 5.33e-01 | 0.1439 |
9031 | BAZ1B | GSM5353236_PA_PR5251_T1_S7_L001 | Human | Prostate | Tumor | 4.98e-08 | 7.52e-01 | 0.1608 |
9031 | BAZ1B | GSM5353237_PA_PR5251_T2_S8_L001 | Human | Prostate | Tumor | 2.49e-03 | 7.43e-01 | 0.1622 |
9031 | BAZ1B | GSM5353240_PA_PR5254_T1_S15_L001 | Human | Prostate | Tumor | 8.24e-13 | 6.13e-01 | 0.1575 |
9031 | BAZ1B | GSM5353243_PA_PR5261_T1_S23_L002 | Human | Prostate | Tumor | 1.65e-08 | 4.50e-01 | 0.1545 |
9031 | BAZ1B | GSM5353244_PA_PR5261_T2_S24_L002 | Human | Prostate | Tumor | 2.43e-12 | 6.45e-01 | 0.1569 |
9031 | BAZ1B | P1_S1_AK | Human | Skin | AK | 2.72e-06 | 3.06e-01 | -0.3399 |
9031 | BAZ1B | P4_S8_cSCC | Human | Skin | cSCC | 7.60e-03 | 1.10e-01 | -0.3095 |
9031 | BAZ1B | P5_S10_cSCC | Human | Skin | cSCC | 8.18e-18 | 3.60e-01 | -0.299 |
9031 | BAZ1B | P1_cSCC | Human | Skin | cSCC | 1.98e-09 | 5.51e-01 | 0.0292 |
Tissue | Expression Dynamics | Abbreviation |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/BAZ1B_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/BAZ1B_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/BAZ1B_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/BAZ1B_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/BAZ1B_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/BAZ1B_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
BAZ1B | SNV | Missense_Mutation | novel | c.3566N>G | p.Val1189Gly | p.V1189G | Q9UIG0 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-5L-AAT0-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
BAZ1B | SNV | Missense_Mutation | | c.3100N>G | p.Leu1034Val | p.L1034V | Q9UIG0 | protein_coding | tolerated(0.19) | probably_damaging(0.991) | TCGA-A1-A0SI-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
BAZ1B | SNV | Missense_Mutation | rs782432522 | c.1270C>T | p.Pro424Ser | p.P424S | Q9UIG0 | protein_coding | tolerated(0.34) | benign(0.031) | TCGA-A2-A0CX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
BAZ1B | SNV | Missense_Mutation | novel | c.1814N>A | p.Thr605Lys | p.T605K | Q9UIG0 | protein_coding | deleterious(0.05) | possibly_damaging(0.829) | TCGA-A2-A25A-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Cytoxan | SD |
BAZ1B | SNV | Missense_Mutation | | c.2584N>A | p.Glu862Lys | p.E862K | Q9UIG0 | protein_coding | tolerated(0.39) | benign(0.015) | TCGA-A8-A06Q-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
BAZ1B | SNV | Missense_Mutation | | c.1556G>A | p.Arg519Gln | p.R519Q | Q9UIG0 | protein_coding | tolerated(0.57) | benign(0.009) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
BAZ1B | SNV | Missense_Mutation | | c.1476N>T | p.Arg492Ser | p.R492S | Q9UIG0 | protein_coding | deleterious(0.02) | benign(0.01) | TCGA-AN-A0AS-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
BAZ1B | SNV | Missense_Mutation | | c.146N>A | p.Ile49Asn | p.I49N | Q9UIG0 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-BH-A0AY-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | | SD |
BAZ1B | SNV | Missense_Mutation | novel | c.2438A>G | p.Asn813Ser | p.N813S | Q9UIG0 | protein_coding | tolerated(0.71) | benign(0.018) | TCGA-D8-A1XK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicine+cyclophosphamide | SD |
BAZ1B | SNV | Missense_Mutation | | c.784T>G | p.Leu262Val | p.L262V | Q9UIG0 | protein_coding | tolerated(0.16) | probably_damaging(0.991) | TCGA-D8-A1XK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicine+cyclophosphamide | SD |